HOWL - Werewolf Therapeutics, Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

HOWL

WEREWOLF THERAPEUTICS, INC.

NASDAQ

$0.97

▲ UP 2.38% (0.02)

KEY STATISTICS

Market Cap$46.43 M

52w High$2.38

52w Low$0.27

Dividend Yield—

Frequency—

P/E-1.27

Volume484.68K

Shares Out.48.60M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Daniel J. Hicklin

COMPENSATION 2026

Salary$608,237

Stock Awards$0

Incentive Plan Pay$0

All Other Comp.$12,857

Total$2,545,599

ABOUT

SECTOR

Healthcare

WENT PUBLIC

April 30, 2021

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

PRICE TARGET

Target High$12.00

Target Low$1.00

Target Median$6.50

Target Consensus$6.50

UPCOMING EARNINGS

DateNov 3, 2026

DayTuesday

Rev. Est.$18.31M

NOV

TUE

PRICE

$0.97 ▲ UP 2.38% (+$0.02)

About Werewolf Therapeutics, Inc.

https://werewolftx.com ↗

Werewolf Therapeutics, Inc. develops immune-stimulating, conditionally activated biotherapeutics for cancer treatment, with lead candidates targeting solid tumors and lymphomas using its proprietary PREDATOR platform.

INDUSTRY

Biotechnology

A PRODUCT WEREWOLF THERAPEUTICS, INC. IS KNOWN FOR

WTX-124

WTX-124 is a conditionally activated IL-2 INDUKINE molecule in clinical trials for solid tumors, designed to activate within tumors to stimulate immune responses while minimizing toxicity, showing promising Phase 1/1b results.